02346nas a2200205 4500000000100000008004100001260003200042653002000074653002600094653002500120653001800145653003400163653004100197100002600238700001600264245010300280300001100383520172100394022002502115 2026 d c09/2026bInforma UK Limited10aChagas' disease10aculture-free genomics10aGenomic Surveillance10aLeishmaniasis10acapture-enrichment sequencing10aselective whole-genome amplification1 aHernandez-Valencia JC1 aRamírez JD00aCulture-free genomics: a shift toward genome-wide applications in Chagas disease and leishmaniasis a1 - 153 a

Introduction

Chagas disease and leishmaniasis remain major neglected tropical diseases, with diagnosis and surveillance constrained by low parasite burden, multiclonal infections, and complex parasite biology. Traditional culture-dependent and targeted molecular approaches fail to capture the full genomic diversity of Trypanosoma cruzi and Leishmania spp. limiting clinical and epidemiological utility.

Areas covered

We review the evolution from early sequencing to second- and third-generation platforms, highlighting culture-free detection and genomic surveillance. We discuss enrichment strategies (selective whole-genome amplification (SWGA) and capture-enrichment sequencing (CES)) addressing low parasite DNA abundance in complex samples, alongside metagenomics and portable sequencing for field-based surveillance and diagnostics. We further explore how direct-from-host data can improve diagnostics, enhance transmission surveillance, support treatment monitoring, and guide control strategies.

Expert opinion

Culture-free genomic approaches represent a transformative advance in kinetoplastid research, providing resolution that culture-dependent methods cannot deliver. Their diagnostic contribution is at present largely indirect, operating through the identification of improved molecular and serological targets rather than through sequencing as the assay itself. Persistent barriers of cost, infrastructure, standardization, and bioinformatics capacity, together with the absence of formal clinical validation, currently confine these methods to research and surveillance settings.

 a1473-7159, 1744-8352